Johnson & Johnson (FRA:JNJ)
135.84
+1.54 (1.15%)
At close: Jun 6, 2025, 10:00 PM CET
Johnson & Johnson Employees
Johnson & Johnson had 138,100 employees as of December 29, 2024. The number of employees increased by 6,200 or 4.70% compared to the previous year.
Employees
138,100
Change (1Y)
6,200
Growth (1Y)
4.70%
Revenue / Employee
€597,179
Profits / Employee
€145,800
Market Cap
327.11B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 138,100 | 6,200 | 4.70% |
Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
Jan 1, 2023 | 152,700 | 11,000 | 7.76% |
Jan 2, 2022 | 141,700 | 7,200 | 5.35% |
Jan 3, 2021 | 134,500 | 2,300 | 1.74% |
Dec 29, 2019 | Pro | Pro | Pro |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Jan 1, 2017 | Pro | Pro | Pro |
Jan 3, 2016 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
SAP SE | 109,121 |
Siemens Aktiengesellschaft | 327,000 |
Deutsche Telekom AG | 198,194 |
Allianz SE | 156,626 |
Rheinmetall AG | 28,539 |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
Siemens Energy AG | 98,000 |
Siemens Healthineers AG | 72,000 |
Johnson & Johnson News
- 3 days ago - Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector? - Market Watch
- 6 days ago - Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation - Benzinga
- 6 days ago - Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma - Benzinga
- 6 days ago - DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity - PRNewsWire
- 6 days ago - Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients - PRNewsWire
- 6 days ago - Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma - PRNewsWire
- 6 days ago - Johnson & Johnson's AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care - GlobeNewsWire
- 6 days ago - Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC - PRNewsWire